News for Keros Therapeutics Stock (KROS)

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

GlobeNewsWire • 11/07/22

Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047

GlobeNewsWire • 11/03/22

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

GlobeNewsWire • 11/03/22

Why Shares of Keros Therapeutics Rose 10.2% This Week

The Motley Fool • 10/14/22

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

GlobeNewsWire • 09/12/22

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

GlobeNewsWire • 08/04/22

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

GlobeNewsWire • 06/13/22

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

GlobeNewsWire • 06/10/22

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

GlobeNewsWire • 05/18/22

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

GlobeNewsWire • 05/17/22

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

GlobeNewsWire • 05/12/22

Keros Therapeutics Reports First Quarter 2022 Financial Results

GlobeNewsWire • 05/05/22

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

GlobeNewsWire • 03/09/22

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewsWire • 02/11/22

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

GlobeNewsWire • 12/13/21

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

GlobeNewsWire • 12/13/21

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

GlobeNewsWire • 11/04/21

Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

GlobeNewsWire • 11/04/21

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting

GlobeNewsWire • 10/04/21

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

GlobeNewsWire • 08/05/21

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

GlobeNewsWire • 08/02/21

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

GlobeNewsWire • 06/22/21

Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association

GlobeNewsWire • 05/12/21

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

GlobeNewsWire • 05/06/21

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

GlobeNewsWire • 03/25/21